NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
40 hedge funds and large institutions have $3.85M invested in NeuBase Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 8 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
18% less funds holding
Funds holding: 49 → 40 (-9)
42% less capital invested
Capital invested by funds: $6.65M → $3.85M (-$2.8M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
90% less call options, than puts
Call options by funds: $6K | Put options by funds: $60K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$605K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$409K |
| 3 |
Renaissance Technologies
New York
|
+$188K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$70.9K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$48.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$306K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$88K |
| 3 |
BIC
Beach Investment Counsel
West Conshohocken,
Pennsylvania
|
-$66K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$41K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$38K |
NBSE Hedge Fund Activity: Q1 2017 in Review
40 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2017, worth a combined $3.85M — down 42% from $6.65M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NBSE and 3 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 9 added.
The largest buyer was BlackRock, opening a new position worth an estimated $605K. The largest seller was Knoll Capital Management, exiting entirely with an estimated $306K sold.
- 40 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2017, down from 49 in Q4 2016.
- Funds reported $3.85M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2017, down 42% quarter-over-quarter.
- 3 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2017 and 8 closed out, a net change of -5 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $605K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2017 was Knoll Capital Management, an estimated $306K sold.
Based on aggregated 13F filings for Q1 2017.